6-K
GSK plc (GSK)
6-K
2020-02-20
For: 2020-02-20
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2020
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Mr R Connor | ||
| b) | Position/status | President,<br>Global Vaccines | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 43,760 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | |
| a) | Name | Ms D Conrad | ||
| b) | Position/status | SVP,<br>Human Resources | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | Following the vesting of awards granted in 2017 under the Company's<br>2017 Performance Share Plan, Ms Conrad received a cash amount of<br>approximately 152,000 (less applicable tax withholding) which<br>is equal to the market value of the number of Ordinary Shares which<br>would otherwise have been transferred to her. | ||
| c) | Price(s)<br>and volume(s) | Volume(s) | ||
| 9,168 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-19 | ||
| f) | Place<br>of the transaction | N/A |
All values are in British Pounds.
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Mr J Ford | ||
| b) | Position/status | SVP<br>& General Counsel | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br>ISIN: US37733W1053 | ||
| b) | Nature<br>of the transaction | The sale of ADSs to meet tax liabilities on the vesting of awards<br>granted in 2017 under the Company's 2017 Performance Share<br>Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $43.544 | 2,454 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr N Hirons | ||
| b) | Position/status | SVP,<br>Global Ethics & Compliance | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 16,122 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms S Jackson | ||
| b) | Position/status | SVP,<br>Global Communications & CEO Office | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 4,309 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr D Jackson | ||
| b) | Position/status | PCA of<br>Ms S Jackson (SVP, Global Communications & CEO<br>Office) | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 1,111 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr B McNamara | ||
| b) | Position/status | CEO,<br>GSK Consumer Healthcare | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br>ISIN: US37733W1053 | ||
| b) | Nature<br>of the transaction | The sale of ADSs to meet tax liabilities on the vesting of awards<br>granted in 2017 under the Company's 2017 Performance Share<br>Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $43.544 | 33,055 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr L Miels | ||
| b) | Position/status | President<br>Global Pharmaceuticals | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 65,213 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr D Redfern | ||
| b) | Position/status | Chief<br>Strategy Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 31,324 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr R Simard | ||
| b) | Position/status | President,<br>Pharmaceuticals Supply Chain | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 4,309 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Mr P Thomson | ||
| b) | Position/status | President,<br>Global Affairs | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 21,650 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms D Waterhouse | ||
| b) | Position/status | CEO of<br>ViiV Healthcare | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 5,909 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Ms V Whyte | ||
| b) | Position/status | Company<br>Secretary | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GlaxoSmithKline plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br><br><br>ISIN: GB0009252882 | ||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2017 under the Company's 2017 Performance<br>Share Plan. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| £16.597 | 4,309 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2020-02-18 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GlaxoSmithKline plc | |
|---|---|
| (Registrant) | |
| Date: February<br>20, 2020 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GlaxoSmithKline plc |